11月10日起，满13周岁女孩免费接种HPV疫苗！

Core Viewpoint - The inclusion of the HPV vaccine in the national immunization program represents a significant commitment to women's health in China, aiming to reduce the burden of cervical cancer and promote public health [4][7]. Group 1: HPV Vaccine Implementation - The HPV vaccine will be available for free to girls who turn 13 years old after November 10, 2011, starting from November 10, 2025, with a total of two doses administered six months apart [4]. - In 2022, there were approximately 151,000 new cases of cervical cancer and about 56,000 deaths in China, highlighting the urgent need for preventive measures [4]. - The initiative aims to improve vaccination rates and reduce disparities in access among different regions and income groups, ensuring equitable health services for the target population [4][6]. Group 2: Immunization Effectiveness - Vaccinating girls at the age of 13 is expected to yield higher antibody levels and more durable protection against HPV [5]. - The decision to target 13-year-old girls for free vaccination is based on considerations of effectiveness, cost-benefit, and operational feasibility [4]. Group 3: Vaccine Production and Capacity - The domestic production of the bivalent HPV vaccine is handled by two companies, with an annual production capacity of 55 million doses, sufficient to meet market demand [6]. - All vaccines produced have received pre-certification from the World Health Organization, ensuring their quality and safety [6]. Group 4: Broader Health Impact - The inclusion of the HPV vaccine in the national immunization program marks a new phase in China's immunization efforts, contributing to global health equity [7]. - The initiative involves collaboration across multiple departments to ensure smooth implementation and effective monitoring of vaccination and associated risks [7].